UBS Group
FRTX

UBS Group’s Fresh Tracks Therapeutics, Inc. Common Stock FRTX Stock Holding History

UBS Group’s Portfolio FRTX Stock Details FRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-1
Closed -$1K – 8329
2015
Q4 		$1K Hold
1
– – ﹤0.01% 8189
2015
Q3 		$1K Hold
1
– – ﹤0.01% 8254
2015
Q2 		$2K Hold
1
– – ﹤0.01% 8229
2015
Q1 		$3K Hold
1
– – ﹤0.01% 8357
2014
Q4 		$3K Buy
+1
New +$3.54K ﹤0.01% 9292

Other funds holding FRTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
CSS
Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

UBS Group's FRTX Position: Q2 2023 in Review

UBS Group sold out of Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) in Q2 2023, closing a stake of 6,462 shares — an estimated $4.26K sold.

UBS Group first reported a position in FRTX in Q4 2014 and held it in 29 quarters. The position peaked at $95K in Q2 2021. 15 funds tracked by Wall St. Rank hold FRTX as of Q2 2023.

  • UBS Group reported no remaining Fresh Tracks Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • UBS Group sold 6,462 Fresh Tracks Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $4.26K.
  • UBS Group first reported a position in Fresh Tracks Therapeutics, Inc. Common Stock in Q4 2014 and held it in 29 quarters.
  • UBS Group's Fresh Tracks Therapeutics, Inc. Common Stock position peaked at $95K in Q2 2021.
  • 15 funds tracked by Wall St. Rank held Fresh Tracks Therapeutics, Inc. Common Stock as of Q2 2023.

Based on UBS Group's 13F filing for Q2 2023, filed 11 Aug 2023.